Spin-off

LiMM is the biopharmaceutical company harnessing the molecular cross-talk between neuronal and innate lymphoid cells within peripheral tissues. By decoding the language of the neuroimmune cross-talk, we are developing first-in-class therapeutic products – NRILs: neuronal reprogrammers of innate lymphocytes – to preserve health and treat inflammatory, infectious and metabolic diseases. We are bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients.